Accelr8 Announces First European Presentation of Rapid Diagnostic Results for New Drug Resistance Test
March 01 2011 - 8:00AM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced
that one of its outside principal investigators received acceptance
to present results of a new study in Europe. Researchers from the
Washington University in St. Louis School of Medicine (the
Barnes-Jewish Hospital) will present at the 21st annual ECCMID to
be held May 7-10, 2011 in Milan, Italy. ECCMID is the European
Congress of Clinical Microbiology and Infectious Disease,
www.eccmid-icc2011.org. It is a major international meeting for
professionals in clinical microbiology and Infectious Diseases
Medicine.
The study will describe alternative new tests, including
Accelr8’s BACcel™ rapid diagnostic system, to identify an important
new type of antibiotic resistance expressed by “Staph” bacteria.
Standard culturing methods are unable to detect this new type of
resistance, abbreviated as “hVISA.”
Staph often causes simple infections, but also causes
life-threatening hospital-acquired infections. “MRSA” is the type
of broadly drug resistant, dangerous Staph strain frequently cited
in news stories as a “superbug.” Physicians most often prescribe
vancomycin if they suspect that a MRSA strain causes an infection.
Staph variants have now emerged with declining vancomycin
susceptibility. hVISA strains appear to be susceptible in standard
culturing tests, but careful analysis in specialized research labs
reveals important differences that indicate possible resistance.
Since vancomycin is the cornerstone drug for suspected MRSA, hVISA
may present a serious new threat.
Unlike other methods, the BACcel™ system eliminates the need for
prior culturing, thereby reporting results on the same day rather
than the 2-3 days required by culturing methods. The new BACcel™
test for hVISA joins tests for other resistance types intended to
be performed at the same time on the same patient specimen.
According to David Howson, Accelr8’s president, “The new
presentation gives the large international community a close look
at the BACcel™ system concept and its performance. The new test may
help investigators perform more definitive clinical studies to
assess the spread of this emerging new threat,” Howson
concluded.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection.
Accelr8 is developing a rapid analytical platform for infectious
pathogens, the BACcel™ system, based on its innovative surface
coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology
for use in applications outside of Accelr8’s own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024